Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetology & Metabolic Syndrome
Published in: Diabetology & Metabolic Syndrome 1/2015

Open Access 01-12-2015 | Short report

Reduced Slc2a4/GLUT4 expression in subcutaneous adipose tissue of monosodium glutamate obese mice is recovered after atorvastatin treatment

Authors: Ana Cláudia Poletto, Aline David-Silva, Aline Pedro de Melo Yamamoto, Ubiratan Fabres Machado, Daniela Tomie Furuya

Published in: Diabetology & Metabolic Syndrome | Issue 1/2015

Login to get access

Abstract

Background

Decreased expression of glucose transporter protein GLUT4, encoded by the solute carrier 2A4 (Slc2a4) gene, is involved in obesity-induced insulin resistance. Local tissue inflammation, by nuclear factor-κB (NFκB)-mediated pathway, has been related to Slc2a4 repression; a mechanism that could be modulated by statins. Using a model of obesity with insulin resistance, this study investigated whether (1) inflammatory markers and Slc2a4 expression are altered; (2) atorvastatin has beneficial effects on inflammation and Slc2a4 expression; and (3) inhibitor of NFκB (IKK)/NFκB pathway is involved in subcutaneous adipose tissue (SAT).

Findings

Obese mice showed insulin resistance, decreased expression of Slc2a4 mRNA (66%, P < 0.01) and GLUT4 protein (30%, P < 0.05), and increased expression of interleukin 6 (Il6) mRNA (44%, P < 0.05) in SAT. Obese mice treated with atorvastatin had enhanced in vivo insulin sensitivity, besides increased Slc2a4/GLUT4 expression and reduced Il6 expression in SAT. No alterations of tumor necrosis factor-α, interleukin 1β and adiponectin expression or IKKα/β activity in SAT of obese mice or obese mice treated with atorvastatin were observed.

Conclusions

Atorvastatin has beneficial effect upon glycemic homeostasis, which may be related to its positive impact on Il6 and Slc2a4/GLUT4 expression in SAT.
Literature
1.
Kahn BB. Lilly lecture 1995. Glucose transport: pivotal step in insulin action. Diabetes. 1996;45(45):1644–54.CrossRefPubMed
2.
Furuya DT, Poletto AC, Favaro RR, Martins JO, Zorn TM, Machado UF. Anti-inflammatory effect of atorvastatin ameliorates insulin resistance in monosodium glutamate-treated obese mice. Metabolism. 2010;59:395–9.CrossRefPubMed
3.
Furuya DT, Poletto AC, Freitas HS, Machado UF. Inhibition of cannabinoid CB1 receptor upregulates Slc2a4 expression via nuclear factor-κB and sterol regulatory element-binding protein-1 in adipocytes. J Mol Endocrinol. 2012;49:97–106.CrossRefPubMed
4.
Furuya DT, Neri EA, Poletto AC, Anhê GF, Freitas HS, Campello RS, et al. Identification of nuclear factor-κB sites in the Slc2a4 gene promoter. Mol Cell Endocrinol. 2013;370:87–95.CrossRefPubMed
5.
Papa PC, Seraphim PM, Machado UF. Loss of weight restores GLUT 4 content in insulin-sensitive tissues of monosodium glutamate-treated obese mice. Int J Obes Relat Metab Disord. 1997;21:1065–70.CrossRefPubMed
6.
Shepherd PR, Gnudi L, Tozzo EPR, Yang H, Leach F, Kahn B. Adipose cell hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in adipose tissue. J Biol Chem. 1993;268:22243–6.PubMed
7.
Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91.CrossRefPubMed
8.
Feinstein R, Papa Kanety H, Lunenfeld B, Karasik A. Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem. 1993;268:26055–8.PubMed
9.
Zhang N, Huan Y, Huang H, Song G, Sun S, Shen Z. Atorvastatin improves insulin sensitivity in mice with obesity induced by monosodium glutamate. Acta Pharmacol Sin. 2010;31:35–42.CrossRefPubMedCentralPubMed
10.
Tulloch-Reid MK, Hanson RL, Sebring NG, Reynolds JC, Premkumar A, Genovese DJ, et al. Both subcutaneous and visceral adipose tissue correlate highly with insulin resistance in african americans. Obes Res. 2004;12:1352–9.CrossRefPubMed
11.
12.
13.
Giorgino F, Laviola L, Eriksson JW. Regional differences of insulin action in adipose tissue: insights from in vivo and in vitro studies. Acta Physiol Scand. 2005;183:13–30.CrossRefPubMed
14.
Furuya DT, Binsack R, Machado UF. Low ethanol consumption increases insulin sensitivity in Wistar rats. Braz J Med Biol Res. 2003;36:125–30.CrossRefPubMed
15.
Tomie Furuya D, Binsack R, Onishi ME, Monteiro Seraphim P, Fabres Machado UF. Low ethanol consumption induces enhancement of insulin sensitivity in liver of normal rats. Life Sci. 2005;77:1813–24.CrossRefPubMed
16.
Ferguson RE, Carroll HP, Harris A, Maher ER, Selby PJ, Banks RE. Housekeeping proteins: A preliminary study illustrating some limitations as useful references in protein expression studies. Proteomics. 2005;5:566–71.CrossRefPubMed
17.
Boucher J, Castan-Laurell I, Daviaud D, Guigne C, Buleon M, Carpene C, et al. Adipokine expression profile in adipocytes of different mouse models of obesity. Horm Metab Res. 2005;37:761–7.CrossRefPubMed
18.
Laviola L, Perrini S, Cignarelli AC, Leonardini A, De Stefano F, Cuscito M, et al. Insulin signaling in human visceral and subcutaneous adipose tissue in vivo. Diabetes. 2006;55:952–61.CrossRefPubMed
19.
Berger J, Biswas C, Vicario PP, Strout HV, Saperstein R, Pilch PF. Decreased expression of the insulin-responsive glucose transporter in diabetes and fasting. Nature. 1989;340:70–2.CrossRefPubMed
20.
Abel ED, Peroni O, Kim JK, Kim YB, Boss O, Hadro E, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature. 2001;409:729–33.CrossRefPubMed
21.
Veilleux A, Blouin K, Rhéaume C, Daria M, Marette A, Tchemof A. Glucose transporter 4 and insulin receptor substrate-1 messenger RNA expression in omental and subcutaneous adipose tissue in women. Metabolism. 2009;58:624–31.CrossRefPubMed
22.
Björnholm M, Al-Khalili L, Dicker A, Näslund E, Rössner S, Zierath JR, et al. Insulin signal transduction and glucose transport in human adipocytes: effects of obesity and low calorie diet. Diabetologia. 2002;45:1128–35.CrossRefPubMed
23.
24.
Takeshita S, Kawamura I, Yasuno T, Kimura C, Yamamoto T, Seki J, et al. Amelioration of insulin resistance in diabetic ob/ob mice by a new type of orally active insulin-mimetic vanadyl complex: bis(1-oxy-2-pyridinethiolato)oxovanadium(IV) with VO(S(2)O(2)) coordination mode. J Inorg Biochem. 2001;85:179–86.CrossRefPubMed
25.
Juge-Aubry CE, Somm E, Giusti V, Pernin A, Chicheportiche R, Verdumo C, et al. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes. 2003;52:1104–10.CrossRefPubMed
26.
Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun. 2003;311:372–9.CrossRefPubMed
27.
Silva JL, Giannocco G, Furuya DT, Lima GA, Moraes PAC, Nachef S, et al. NF-kappaB, MEF2A, MEF2D and HIF1-a involvement on insulin- and contraction-induced regulation of GLUT4 gene expression in soleus muscle. Mol Cell Endocrinol. 2005;240:82–93.CrossRefPubMed
Metadata
Title
Reduced Slc2a4/GLUT4 expression in subcutaneous adipose tissue of monosodium glutamate obese mice is recovered after atorvastatin treatment
Authors
Ana Cláudia Poletto
Aline David-Silva
Aline Pedro de Melo Yamamoto
Ubiratan Fabres Machado
Daniela Tomie Furuya
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2015
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-015-0015-6

Other articles of this Issue 1/2015

Diabetology & Metabolic Syndrome 1/2015 Go to the issue

Review

Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins

Short report

Prospective evaluation of glutamine and phospholipids levels in first degree relatives of patients with Type 1 Diabetes from a multiethnic population

Erratum

Erratum: Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats

Short report

New digital tool to facilitate subcutaneous insulin therapy orders: an inpatient insulin dose calculator

Research

Relationship between glycemic control and histochemical myeloperoxidase activity in neutrophils in patients with type 2 diabetes

Review

Regulation of hepatic TRB3/Akt interaction induced by physical exercise and its effect on the hepatic glucose production in an insulin resistance state
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits